A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Phase 1 Active not recruiting 65 enrolled Genentech, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.

Timeline

Start: 2021-05-13
Primary completion: 2026-12-31
Completion: 2026-12-31

Publications

Moschos SJ. War against NRAS-Mutant Melanoma Using Targeted Therapies Remains Challenging. Clin Cancer Res. 2022 Jul 15;28(14):2977-2979. doi: 10.1158/1078-0432.CCR-22-1256.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Belvarafenib	Small molecule	—	—
Subject	Cobimetinib	Small molecule	—	—
Subject	Nivolumab	Monoclonal antibody	—	Intravenous

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Summary

Timeline

Publications

Drugs

Indications